Our results, with real-world OS estimates in patients with advanced NSCLC and ECOG PS 0–1 receiving a PD-(L)1 inhibitor-based regimen in front-line therapy were generally similar to findings reported in pivotal PD-(L)1 inhibitor clinical trials for regulatory approved regimens that were available during the time period of this study. The gene discussed is CD274; the disease is non-small cell lung carcinoma.